Tivozanib (Fotivda®)
Dokument
Factsheet
Spezifizierung
Nierenzellkarzinom (Hypernephrom)
» fortgeschritten
» Erst- u. Zweitlinientherapie
Stand
Mai 2020
Dies ist die aktuell gültige Version des Dokuments
1Tivozanib, RCC, advanced, first and second line
1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/48 results for control, results for new therapy9 hazard ratio for new therapy10 n. s. not significant19 Memorial Sloan Kettering Cancer Center Score (Motzer Score)20 Memorial Sloan Kettering Cancer Center Score (Motzer Score)21 Memorial Sloan Kettering Cancer Center Score (Motzer Score)